Biomarker Type: Proteomic
-
An Integrated Risk Predictor for Pulmonary Nodules
-
Development of scores reflective of biological processes underlying human disease states from mass spectrometry of serum.
-
Predicting clinical outcomes using proteomics in non-small cell lung cancer – The past, present, and future
-
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat® Good versus VeriStrat® Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
-
Cost-effectiveness of an autoantibody test as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules
-
Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer
-
A Pre‐Treatment Mass Spectrometry‐Based Serum Proteomic Test is Able to Stratify Patients with Ovarian Cancer Receiving Adjuvant Chemotherapy According to Overall and Disease‐Free Survival and Identify Patients Likely to Exhibit Chemo‐Resistance
-
Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
-
Precision Medicine: Estimated Clinical and Economic Outcomes of Using a Predictive and Prognostic Biomarker to Avoid Ineffective Therapies in Advanced Non-Small Cell Lung Cancer.
-
Integration of the Clin-ToF into the VeriStrat clinical testing workflow to generate serum protein profiles for prognosis and therapeutic guidance in NSCLC